Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. James R. Berenson discusses the role of b-cell maturation antigen (BCMA) in predicting outcomes and monitoring patients with multiple myeloma or chronic lymphocytic leukemia. © 2019 Imedex, an HMP Company
Role of BCMA in Predicting Outcomes and Monitoring MM and CLL
